Evidence map›Paper›PMID 38928320›Full record

ArticleInternational journal of molecular sciences2024

The Anti-Atherosclerotic Effects of Endothelin Receptor Antagonist, Bosentan, in Combination with Atorvastatin-An Experimental Study.

Marianna Stasinopoulou, Nikolaos Kostomitsopoulos, Nikolaos P E Kadoglou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Marianna StasinopoulouCenter of Clinical, Experimental Surgery, and Translational Research, Biomedical Research Foundation, Academy of Athens, 115 27 Athens, Greece.ORCID 0000-0003-3365-891X
Nikolaos KostomitsopoulosCenter of Clinical, Experimental Surgery, and Translational Research, Biomedical Research Foundation, Academy of Athens, 115 27 Athens, Greece.ORCID 0000-0003-4787-5106
Nikolaos P E KadoglouMedical School, University of Cyprus, 2029 Nicosia, Cyprus.ORCID 0000-0002-7830-3488

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bosentan, an endothelin receptor antagonist (ERA), has potential anti-atherosclerotic properties. We investigated the complementary effects of bosentan and atorvastatin on the progression and composition of the atherosclerotic lesions in diabetic mice. Forty-eight male

Indexed as

AtherosclerosisAtorvastatinBosentanEndothelin Receptor AntagonistsAnimalsChemokine CCL2CollagenDiabetes Mellitus, ExperimentalDiet, High-FatDrug Therapy, CombinationMaleMiceMice, KnockoutPlaque, AtheroscleroticTissue Inhibitor of Metalloproteinase-1Tumor Necrosis Factor-alphaAtorvastatinBosentanChemokine CCL2CollagenEndothelin Receptor AntagonistsTissue Inhibitor of Metalloproteinase-1Tumor Necrosis Factor-alphaatherosclerosisatorvastatinbosentanendothelin receptor antagonist (ERA)matrix metalloproteinasesplaque stability

Identifiers

PMID38928320
PMCPMC11203450

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.